FDA moves to restrict compounded GLP-1 ingredients and names Hims & Hers

The U.S. Food and Drug Administration said on February 6, 2026 that it plans to limit GLP-1 active pharmaceutical ingredients (APIs) headed for compounded drugs that are not FDA-approved and that companies sell to consumers at scale ^[1]. The announcement names Hims & Hers, along with other compounding pharmacies, as mass marketers of such products ^[1].

The statement came from FDA Commissioner Martin A. Makary, M.D., M.P.H. The release lists his tenure as April 2025 to May 2026 ^[1]. Makary wrote that the steps are meant to shield consumers from drugs whose quality, safety and effectiveness the agency has no way to confirm ^[1]. Potential violations of the Federal Food, Drug, and Cosmetic Act, he added, are taken seriously ^[1].

The agency said it will use "all available compliance and enforcement tools" in its authorities to address unsupported claims and related public health concerns ^[1]. Manufacturers, distributors and marketers of unapproved compounded GLP-1 products were told that failing to adequately address violations "may result in legal action without further notice, including, without limitation, seizure and injunction" ^[1].

Separately, the FDA said it is moving against misleading direct-to-consumer advertising, after warning letters went out in the fall of 2025 ^[1]. Under the agency's position, promotional materials cannot describe a compounded product as a generic version of an FDA-approved drug or as the same as one. Nor can they say that a compounded drug uses the same active ingredient as an approved drug, or that it is clinically proven to produce results for patients ^[1].

Much about the plan remains unspecified. The FDA did not say what form the ingredient restrictions would take, when they would start, or which ingredients or suppliers they would cover. The number of fall 2025 warning letters, who received them and what they required were not included. No seizure or injunction has been reported as filed, and no response from Hims & Hers was included in the announcement ^[1].

Why it matters for patients

People who get a GLP-1 from a compounding pharmacy or through a telehealth subscription are taking a product that has not gone through the FDA's approval process ^[1]. The agency's stated concern is that it cannot vouch for what is in those products or how well they work ^[1]. If the ingredient supply tightens, the practical effects could eventually reach refills, prices or availability, but nothing in the announcement addresses individual orders, and the timing is not yet known.

The advertising rules touch a common comparison. A claim that a compounded product is the same as, or a generic of, an approved drug, or that it contains the same active ingredient or is proven to work, is the kind of claim the FDA says is off limits ^[1]. Whether a person is taking an FDA-approved GLP-1 or a compounded one is something a prescriber or pharmacist can confirm; the two are reviewed under different standards.

What happens next

The FDA framed the restrictions as something it intends to do, without a date or a mechanism attached. It has not said whether it will proceed through guidance, a rule, or controls on supply and imports, and it has not promised a warning period before acting ^[1]. The agency's background materials cover compounding while drugs sit on the national shortage list and compounded products that amount to copies of commercially available drugs, but the announcement did not explain how either policy would be used here ^[1].